With a new CEO, a new subsidiary, a newly approved gene therapy and three R&D centers under construction on three different continents, change is coming fast for CSL Limited. Established more than a ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...

Exclusive option agreement for CSL to acquire all issued and outstanding shares of the company, dependent on Phase 3 data LEIDEN, Netherlands, September 16, 2025--(BUSINESS WIRE)--VarmX, a biotech ...

SYDNEY--Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.

Plans to spin off CSL Seqirus into listed entity by next June Seeks annualised savings of up to $550 million over three years Lifts dividend and plans A$750 million share buyback Underlying profit up ...

CSL is coming for one of Takeda’s fastest-growing products. Phase 3 data on CSL’s garadacimab in a rare disease suggest the monoclonal antibody may have an edge over Takeda’s Takhzyro in terms of ...